Recent studies have found that in addition to promoting DC maturation by inducing the expression of type I IFN, cGAMP or other STING agonists can directly activate DCs in vitro, and enhance presentation of tumor-associated antigens to CD8+ T cells [86, 87]. This evidence concerns the gene CD8A and neoplasm.